Axovant Sciences Announces Pricing of $40 Million Public Offering of Common Shares
March 14 2019 - 7:00AM
Axovant Sciences (Nasdaq: AXGT) ("Axovant") today announced the
pricing of its underwritten public offering of 26,666,667 of its
common shares at a price to the public of $1.50 per
share. Gross proceeds to Axovant from the offering are expected to
be approximately $40,000,000 before deducting underwriting
discounts and commissions and estimated offering expenses.
All of the common shares are being offered by Axovant. In
connection with this offering, Axovant has granted the underwriters
a 30-day option to purchase up to an additional 4,000,000 of its
common shares on the same terms and conditions. The offering
is expected to close on March 18, 2019, subject to customary
closing conditions.
Jefferies and Guggenheim Securities are acting as joint
book-running managers for the offering. JMP Securities is acting as
lead manager.
A shelf registration statement relating to the offered common
shares was filed with the Securities and Exchange Commission (SEC),
and was declared effective on January 13, 2017. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering have been filed with the SEC and are available on the
SEC's website, located at www.sec.gov. Copies of the
final prospectus supplement and accompanying base prospectus
related to the offering may be obtained, when available, from
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone
at (877) 821-7388, or by e-mail at
Prospectus_Department@Jefferies.com; and Guggenheim Securities,
LLC, Attention: Equity Syndicate Department, 330 Madison Avenue,
New York, NY 10017 or by telephone at (212) 518-5548, or by email
at GSEquityProspectusDelivery@guggenheimpartners.com.
This announcement is neither an offer to sell nor a solicitation
of an offer to buy any of these securities, and shall not
constitute an offer, solicitation, or sale in any jurisdiction in
which such offer, solicitation, or sale is unlawful.
About Axovant Axovant, part of the
Roivant family of companies, is a clinical-stage gene therapy
company focused on developing a pipeline of innovative product
candidates for debilitating neurological and neuromuscular
diseases. The company’s current pipeline of gene therapy candidates
targets GM1 gangliosidosis, GM2 gangliosidosis (including Tay-Sachs
disease and Sandhoff disease), Parkinson’s disease, oculopharyngeal
muscular dystrophy (OPMD), amyotrophic lateral sclerosis (ALS) and
frontotemporal dementia. Axovant is focused on accelerating product
candidates into and through clinical trials with a team of experts
in gene therapy development and through external partnerships with
leading gene therapy organizations.
Contacts:
Mike BeyerSam Brown Inc.(312)
961-2502mikebeyer@sambrown.commedia@axovant.com
Investors
Tricia Truehart(631) 892-7014investors@axovant.com
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jul 2023 to Jul 2024